The +3% gain in PPV overall and +7% in the ACPA-negative group would allow patients with RA to be classified and access treatment at inclusion rather than later (median 6 months of delay), notably for ACPA-negative patients. The gene discussed is PRTN3; the disease is rheumatoid arthritis.